clement, Author at BaseLaunch

Alentis Therapeutics receives FDA Fast Track Designation for ALE.C04

We are pleased to announce that Alentis Therapeutics, a company within our portfolio, has been granted fast track designation by the US FDA for its…

clement13.09.2023

Alentis starts first in-human clinical trial

All Portfolio news

Alentis Therapeutics starts their first-in-human clinical trial

FDA greenlights Alentis Phase 1 protocol study design Alentis to begin transition from pre-clinical to clinical Basel, Switzerland., 04 January 2022 — Alentis Therapeutics, AG…

clement06.01.2022

Anaveon_-startups_Switzerland-credit-Jasmin-Rei

All Portfolio news

Anaveon raises 110 Million Swiss francs in Series B financing

Back in 2017, when we first met Andreas Katopodis, he had the vision to build a company that translates breakthrough science in the field of…

clement17.12.2021

All Interviews Team interviews

Featured Interview: Stephan Emmerth, Director Business Development & Operations, BaseLaunch

Swiss biotech venture accelerator and incubator BaseLaunch was started in 2017 to help launch and grow the next generation of biotech companies. The accelerator has…

clement16.12.2021

All Company interviews Interviews

“We master all the tricks of the trade” Interview with Thomas Fessard CEO of SpiroChem

Founded in 2011, the company moved to Basel in 2017. Today, SpiroChem has gained an excellent reputation for delivering best-in-class chemistry services and works with…

clement01.11.2021

All Features

Building a biotechnology ecosystem

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. The company provides affordable and non-exclusive access to…

clement01.11.2021

All Features

Premier news: KPMG renews its commitment

We are delighted to announce that KPMG, is continuing its partnership with BaseLaunch to help support cutting-edge early-stage biotechs to achieve financing and grow their…

clement01.11.2021

All Features

Several of our companies are looking for experienced biopharma talent

"People Wanted: For hazardous journey. Small wages, bitter cold, long months of complete darkness, constant danger, safe return doubtful. Honor and recognition in case of…

clement01.11.2021

All Portfolio news

Engimmune Therapeutics joins BaseLaunch Portfolio

Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences to engineer highly potent and specific therapies based on…

clement26.10.2021

All Features

China Medical System joins BaseLaunch as latest partner

We are delighted to announce that China Medical System is now part of the BaseLaunch partner portfolio. This is the first Chinese company to partner…

clement20.09.2021

clement

Alentis Therapeutics receives FDA Fast Track Designation for ALE.C04

Alentis Therapeutics starts their first-in-human clinical trial

Anaveon raises 110 Million Swiss francs in Series B financing

Featured Interview: Stephan Emmerth, Director Business Development & Operations, BaseLaunch

“We master all the tricks of the trade” Interview with Thomas Fessard CEO of SpiroChem

Building a biotechnology ecosystem

Premier news: KPMG renews its commitment

Several of our companies are looking for experienced biopharma talent

Engimmune Therapeutics joins BaseLaunch Portfolio

China Medical System joins BaseLaunch as latest partner

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us